Prevention of biliary diseases associated with GLP-1 receptor agonist therapy
Background. In recent years, glucagon-like peptide-1 receptor agonists (GLP-1a) have emerged as pivotal therapeutic agents in the management of metabolic disorders, particularly type 2 diabetes mellitus and obesity. This is due to their ability to improve glycemic control and facilitate weight loss...
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Russo |
| Udgivet: |
Open Systems Publication
2026-04-01
|
| Serier: | Лечащий Врач |
| Fag: | |
| Online adgang: | https://journal.lvrach.ru/jour/article/view/1600 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|